CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 258 enrolled
Drug / intervention
Delgocitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03683719
NCT03683719Phase 2Completed

A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema

LEO Pharma·interventional·Posted Sep 25, 2018·Updated Mar 12, 2025

In Brief

A Phase 2 clinical trial evaluating Delgocitinib cream and Delgocitinib cream vehicle for Chronic Hand Eczema. Completed, enrolled 258 participants across 28 sites in 3 countries.

Detailed Summary

The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark, Germany, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 25, 2018
Enrollment StartNov 28, 2018
Primary CompletionMar 6, 2020
Study CompletionApr 20, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.8 years ago

Interventions

Delgocitinib creamdrug

Cream for topical application.

Delgocitinib cream vehicledrug

The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.